Study Exclusion reasons Remarks Reference(s)
Kawasuji, 2022 - no control group

Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433

 
Falsey, 0 - no control group

Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468

 
BioNTech phase 2 (Walsh), 2020 randomized controlled trial no clinically relevant endpoint phase 1-2 ; dose-escalation : 13 groups of 15 participants  
Pfizer 16-25 years phase 3, 0 randomized controlled trial other very preliminary results from a press release